{
      "ptx_code": "PTX186",
      "chem_name": "Pentamidine",
      "casrn": "100-33-4",
      "dtxsid": "DTXSID7023431",
      "smiles": "NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1",
      "inchikey": "XDRYMKDFEDOLFX-UHFFFAOYSA-N",
      "label": "PTX186 | Pentamidine",
      "drugbank_id": "DB00738",
      "use_class": "Pharmaceutical",
      "tox_class": "Hepatotoxicity; Immunotoxicity; Ototoxicity; Nephrotoxicity; Cardiotoxicity",
      "chem_name_user": "Pentamidine",
      "mw_g_mol": "340.427",
      "solubility_h2o_mol_liter": "0.00550295",
      "source_solubility_h2o": "COMPTOX (OPERA)",
      "henry_coefficient_atm_m3_mol": "6.27467e-12",
      "source_henry": "COMPTOX",
      "log_kaw_kh_rt": "9.5907187816713",
      "source_kaw": "LSER eq 1 exp. Descriptors",
      "pka_acid": "",
      "pka_base": "",
      "source_pka": "ACD/GALAS",
      "log_kow_liter_liter": "2.336",
      "source_kow": "",
      "log_dlipw_ph74_liter_liter": "0.779999999999999",
      "source_dlipw": "Kow QSAR (\u00e2\u02c6\u2020mw = 1)",
      "freely_dissolved_fraction": "0.923319554823379",
      "density_kg_liter": "",
      "source_density": "COMPTOX",
      "baseline_drerio": "28041.4198545369",
      "baseline_dmagna": "7592.76572646525",
      "baseline_celegans": "16527.2272994873",
      "baseline_xlaevis": "2557.08991853431",
      "baseline_dmelanogaster": "68895.3641554649",
      "baseline_cells": "0.00467327432689024",
      "baseline_cells_generic_micromole_liter_free_ec10": "0.00431492557107183",
      "moa_drugbank": "The mode of action of pentamidine is not fully understood. It is thought that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids, and proteins.",
      "protein_binding": "69%",
      "moa_t3db": "",
      "aop": [
            {
                  "AOP_id": 19,
                  "AOP_name": "Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) "
            },
            {
                  "AOP_id": 61,
                  "AOP_name": "NFE2L2/FXR activation leading to hepatic steatosis "
            }
      ],
      "targets": [
            "Glyceraldehyde-3-phosphate dehydrogenase",
            "Multidrug and toxin extrusion protein 1",
            "Multidrug and toxin extrusion protein 2",
            "Protein S100-B",
            "Protein tyrosine phosphatase type IVA 3",
            "Solute carrier family 22 member 1",
            "Solute carrier family 22 member 2",
            "Solute carrier family 22 member 3",
            "Suppressor of tumorigenicity 14 protein",
            "tRNA (cytosine(38)-C(5))-methyltransferase"
      ]
}